Author | Hannah Slater


FDA Grants Priority Review to Osimertinib for Adjuvant Treatment of Early-Stage EGFRm NSCLC

October 20, 2020

The FDA accepted and granted priority review to the supplemental new drug application for osimertinib (Tagrisso) for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer after complete tumor resection with curative intent.

ctDNA May Be Reliable Predictor of Outcomes with First-Line Immunotherapy for Melanoma

October 19, 2020

Pretreatment circulating tumor DNA was found to be a reliable indicator of patient outcome for those with metastatic melanoma in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line setting.

New Guidance for Testing of Minimal Abnormalities Detected in Cervical Cancer Screening

October 18, 2020

Following the new ASCCP-led national consensus guidelines for managing abnormal cervical cancer screening tests, these new guidelines estimate risk based on an individual’s risk factors, thus allowing for more personalized care management.